Today: 19 May 2026
Qualcomm stock price tumbles on weak forecast as memory crunch hits handset outlook
5 February 2026
2 mins read

Qualcomm stock price tumbles on weak forecast as memory crunch hits handset outlook

New York, Feb 5, 2026, 10:43 EST — Regular session underway.

Qualcomm Incorporated shares dropped $14.21, or 9.5%, to $134.68 in Thursday’s morning session, deepening losses from after-hours trading following a wary forecast linked to tight memory supply. The stock hit a low of $129.98, as the iShares Semiconductor ETF slipped 1.5%.

The selloff hits a well-known weak spot in the handset supply chain: memory components paired with processors inside phones. When device makers struggle to lock down enough memory, handset shipments drop, dragging chip orders down with them.

This is crucial since Qualcomm’s guidance — its revenue and profit outlook — usually influences the wider smartphone chip sector. Investors have been bullish on AI-related semiconductors, yet the consumer device segment reacts sharply whenever inventories are trimmed.

Late Wednesday, Qualcomm, based in San Diego, California, projected fiscal second-quarter revenue between $10.2 billion and $11 billion, with adjusted earnings of $2.45 to $2.65 per share—both figures falling short of Wall Street’s expectations. The chipmaker cited a global memory supply shortage that’s weighing on mobile phone sales. CEO Cristiano Amon told Reuters the forecast miss stems from the memory crunch, adding, “I’m very happy with the business – I just wish we had more memory.” CFO Akash Palkhiwala noted the company anticipates around $6 billion in mobile phone chip sales this quarter. Qualcomm also spotlighted a new AI data center chip line, with Saudi sovereign-wealth-fund-backed AI firm Humain as a customer, which Amon said should remain unaffected by the memory shortage. Reuters

On Thursday, Amon highlighted that memory shortages and rising prices are set to “define the overall scale of the handset industry through the fiscal year.” Qualcomm executives cautioned this squeeze could last into 2027. Arm, which provides the architecture behind many smartphone chips, warned its royalty revenue might take a hit of up to 2% due to the same issues. eToro analyst Zavier Wong noted the results “largely reflect broader industry trends rather than Qualcomm-specific issues.” Reuters

After the forecast, analysts adjusted their targets. MarketScreener, referencing MT Newswires, noted that Bank of America downgraded Qualcomm to neutral. Several firms, including Evercore ISI, Citigroup, Cantor Fitzgerald, and Mizuho, also cut their price targets.

Qualcomm directed investors to its earnings release posted on its investor relations website, adding that the same material would be filed with the U.S. Securities and Exchange Commission via a Form 8-K.

Qualcomm has long aimed to expand its growth beyond just phones, pushing deeper into emerging chip markets. Still, days like today remind investors just how much the handset cycle continues to influence its stock.

The downside is clear-cut. If memory remains tight or costs climb, phone makers might slash production once more. Qualcomm could then be forced to lower its forecasts again, following earlier cuts this week.

Mobile World Congress in Barcelona from March 2-5 is the next big date to watch. The handset supply chain typically drops hints about upcoming build plans there. Traders will be on alert for shifts in memory availability or smartphone demand talk that might either back up Qualcomm’s cautious stance or ease concerns.

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

IREN Drops Again After AI Cloud Plans Get Costlier

IREN Drops Again After AI Cloud Plans Get Costlier

18 May 2026
IREN shares dropped 7.2% to $49.15 Monday after the company acquired its marketing partner Awaken, folding the agency into its operations. The decline followed IREN’s $3 billion convertible-note sale last week to fund a major data-center expansion for AI services. Quarterly revenue fell and net loss widened as the company shifts from Bitcoin mining to AI cloud infrastructure.
Dow Jones drops nearly 300 points as Alphabet AI spending plan rekindles tech jitters
Previous Story

Dow Jones drops nearly 300 points as Alphabet AI spending plan rekindles tech jitters

Lumentum stock whipsaws as AI-linked outlook meets a choppy tape
Next Story

Lumentum stock whipsaws as AI-linked outlook meets a choppy tape

Go toTop